1-(2,6-diazaspiro[3.3]heptan-6-yl)-5,6-dihydro-4h-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine derivatives and related compounds as vasopressin antagonists for the treatment of neuro-psychological disorders
WO2020097609A1
Gpr139 receptor modulators
US2020121236A1
Systems and methods for screening, diagnosing, and stratifying patients
WO2020047253A1
Multimodal biomarkers predictive of transdiagnostic symptom severity
WO2020047224A1
System and method for identifying transdiagnostic features shared across mental health disorders
EP3787481A1
Machine learning-based diagnostic classifier
US2019355439A1
Methods and systems for computer-generated predictive application of neuroimaging and gene expression mapping data
CA3072766A1
Vasopressin receptor antagonists and products and methods related thereto
US2019048013A1
Vasopressin receptor antagonists and products and methods related thereto
